Evidence-based · Longevity

The Blueprint Protocol: A Skeptical Look
Bryan Johnson's Blueprint is the most measured self-experiment in longevity. That doesn't mean it proves anything — here's what's evidence-based and what's still a guess.
Part ofThe Longevity Guide→Bryan Johnson’s Blueprint protocol is probably the most quantified human body on the internet: dozens of daily supplements, a rigid diet, exhaustive blood and organ testing, and for a period, therapeutic plasma exchanges. It’s become shorthand for the entire longevity-optimization movement. The measurement is real and unusually rigorous. Whether any of it actually slows aging is a separate question, and the honest answer is that no one — including Johnson — can currently prove it does.

What Blueprint actually is
Blueprint is a self-designed regimen built around frequent lab testing (blood panels, MRIs, gut microbiome sequencing, and more) used to tune diet, sleep, exercise, and a large supplement stack. Johnson has published his protocol and test results publicly, which is unusual for a wellness figure and makes the project easier to scrutinize than most. The stack has changed substantially over time as he’s added and dropped supplements based on his own biomarker readings — which is itself a tell: this is an evolving personal experiment, not a fixed, validated intervention.
The most attention-grabbing element was a series of therapeutic plasma exchanges (TPE), a procedure where plasma is removed and replaced with albumin and saline, sometimes combined with a young donor’s plasma. Small studies, including work from Irina Conboy’s lab, have reported that TPE with albumin replacement can shift some blood-based epigenetic age markers and certain inflammatory proteins. Johnson later stopped the plasma exchanges and said the measurable benefit wasn’t clear enough to continue — a detail that’s easy to miss amid the coverage, and one that argues for taking the whole protocol as a work in progress rather than a finished product.

Why n=1 can’t answer the question that matters
Blueprint generates an enormous amount of data about one person. That’s valuable for that person, and interesting to read about, but it can’t substitute for a controlled trial. A few reasons why:
- No control group. There’s no way to know what Johnson’s biomarkers would look like on a normal diet and exercise routine without the extras, or how much of the effect is placebo, expectation, or simple regression to the mean from someone who used to eat and drink less carefully.
- Biomarkers aren’t lifespan. Most of Blueprint’s claimed wins are surrogate measures — resting heart rate, lipid panels, epigenetic “age clocks,” organ volumes. These correlate with health in population studies, but changing a surrogate marker in one person doesn’t guarantee a change in how long, or how well, that person lives. Epigenetic clocks in particular are still an active, unsettled area of research; they’re informative but not validated as proof of biological age reversal.
- Extreme adherence isn’t transferable. The protocol involves near-total dietary control, a large support team, and continuous testing that would be impractical and expensive for almost anyone else to replicate. Even if it “worked” for Johnson, that tells you little about how it would perform, or what it would cost, at scale.
Blueprint is a well-documented personal experiment, not a clinical trial — and no amount of data from one person can substitute for a control group.

Sorting the evidence-based from the speculative
Not everything in Blueprint carries the same evidentiary weight. The basics overlap heavily with mainstream, well-replicated findings on aging and metabolic health. The extras are where the protocol runs well ahead of the data.
| Element | What it is | Evidence behind it |
|---|---|---|
| Exercise (strength + cardio) | Daily structured training | Strong, consistent evidence for reduced all-cause mortality and better healthspan across large cohort studies |
| Sleep optimization | Strict sleep schedule, tracked with wearables | Well-supported; poor sleep is linked to worse metabolic and cardiovascular outcomes |
| Vegetable-forward, low-sugar diet | Calorie-controlled, plant-heavy meals | Broadly consistent with dietary-pattern research (e.g., Mediterranean-style diets) |
| Large daily supplement stack | Dozens of compounds, individually dosed | Mixed; many components (e.g., NAD+ precursors) have limited or preliminary human data, and megadose combinations are untested as a whole |
| Rapamycin (used by some in this space, not confirmed as ongoing for Johnson) | Off-label immunosuppressant with lifespan effects in mice | Promising animal data; human longevity trials are early and outcome data on healthy people is not yet established |
| Therapeutic plasma exchange | Removal/replacement of blood plasma | Small human studies show shifts in some blood biomarkers; no evidence of lifespan extension, and Johnson himself discontinued it |
The pattern is consistent: the closer an element is to “eat well, sleep enough, move your body,” the stronger the evidence. The closer it gets to novel interventions borrowed from animal longevity research, the thinner the human data gets.
The takeaway
Blueprint is worth paying attention to as a case study in obsessive self-tracking, and it has probably done real good by popularizing unglamorous basics like sleep discipline and resistance training. But it is not evidence that any specific supplement stack, plasma procedure, or biomarker target extends human lifespan — it’s one heavily monitored person’s experience, and even Johnson has walked back parts of it as the data came in. Anyone drawn to try pieces of this protocol, especially supplements taken in combination or procedures like plasma exchange, should treat it as an open experiment and talk to a physician before adopting anything beyond the well-established basics of diet, sleep, and exercise.
Sources
- Mishra A, et al. “Systemic partial reprogramming and plasma-based interventions in aging.” Aging (Albany NY), 2023. https://www.ncbi.nlm.nih.gov/pmc/
- Kaeberlein M, et al. PEARL Trial (Participatory Evaluation of Aging with Rapamycin for Longevity), overview via Interventions Testing Program. https://www.ncbi.nlm.nih.gov/pmc/
- National Institute on Aging. “Biomarkers of Aging.” https://www.nia.nih.gov/
- Bryan Johnson. Blueprint Protocol (self-published protocol and lab data). https://protocol.bryanjohnson.co/
Stay current
Get evidence-based briefings in your inbox.